Spotlight on pembrolizumab in the treatment of advanced melanoma
نویسندگان
چکیده
Metastatic melanoma is an aggressive cancer with a poor prognosis. Many approved therapies often do not achieve durable responses in patients. This underscores the need for novel therapeutic strategies. Recruiting a robust immune response is an important antineoplastic treatment strategy. Immune checkpoints offer a molecular target for modulating the immune response and a promising therapeutic target in metastatic melanoma. Here we discuss the recent approval of pembrolizumab by the US Food and Drug Administration for the treatment of metastatic melanoma and its impact on future management of the disease.
منابع مشابه
Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
Tumoral melanosis is a form of completely regressed melanoma that usually presents as darkly pigmented lesions suspicious for malignant melanoma. Histology reveals dense dermal and subcutaneous infiltration of melanophages. Pembrolizumab is an antibody directed against programmed death receptor-1 (PD1) and is frontline treatment for advanced melanoma. An 81-year-old man with metastatic melanoma...
متن کاملEstablishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
New therapies targeting the programmed death receptor-1 (PD-1) are changing the outcomes of patients with advanced cancers, with randomized trials reporting improvements in overall survival (OS) compared with standard treatment [1–6]. However, there is debate about whether patients should be selected for treatment with these agents based on expression of the PD-1 ligand, PD-L1. The US Food and ...
متن کاملPembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
The programmed death-1 inhibitor pembrolizumab has demonstrated efficacy and safety in clinical trials for treating advanced (unresectable/metastatic) melanoma. We investigated the real-world utilization of pembrolizumab and associated patient outcomes for advanced melanoma in US community oncology practices. This retrospective, observational study used deidentified data from electronic health ...
متن کاملPD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
On the basis of remarkable antitumor activity, programmed death receptor-1 (PD-1) inhibitors pembrolizumab and nivolumab were approved for the treatment of advanced melanoma in the second-line setting following progression on either CTLA-4 inhibitor ipilimumab or BRAF/MEK inhibitors (for BRAF mutated melanoma). Given hypothesized risk of triggering exacerbations of autoimmune diseases and/or ch...
متن کاملCost-Effectiveness of Pembrolizumab for Unresectable Metastatic Melanoma After Progression with Ipilimumab in England.
REFERENCES Pembrolizumab (MK-3475) is a humanised, anti-programmed cell death 1 (PD-1) monoclonal IgG4 antibody. It is involved in the blockade of immune suppression and reactivation of anergic T-cells in cancer patients. It is believed that due to the high specificity and affinity for PD-1, against which it displays pure antagonist properties, pembrolizumab has the potential to improve the eff...
متن کامل